Literature DB >> 32437868

Prognostic Significance of Perioperative C-Reactive Protein in Resected Non-Small Cell Lung Cancer.

Satoru Okada1, Masanori Shimomura1, Hiroaki Tsunezuka1, Satoshi Teramukai2, Shunta Ishihara1, Junichi Shimada1, Masayoshi Inoue3.   

Abstract

Inflammation is reportedly associated with the development and progression of various malignancies. However, the clinical significance of preoperative and postoperative inflammation in lung cancer patients undergoing surgery is unknown. The relationship between preoperative and postoperative C-reactive protein (CRP), an indicator of inflammation, and survival was retrospectively analyzed in 356 patients who underwent complete resection of pathologic Stage I and II non-small cell lung cancers. Cutoffs for preoperative CRP (CRPpre), postoperative maximum levels of CRP (CRPmax), and postoperative CRP levels 30 days after surgery (CRP30) were determined as 0.2 mg/dL, 6.4 mg/dL, and 0.2 mg/dL, respectively. Patients with CRPprehigh, CRPmaxhigh, or CRP30high status had significantly poorer overall survival (OS) and relapse-free survival (RFS) than those with CRPprelow, CRPmaxlow, or CRP30low. Patients were stratified into 4 groups according to perioperative CRP grades, combining CRPprehigh, CRPmaxhigh, and CRP30high statuses, yielding groups with grades 0, 1, 2, and 3. OS and RFS significantly worsened with increasing grade. After controlling for potential confounders, the multivariate Cox proportional hazard model revealed perioperative CRP grade as an independent poor prognostic factor for OS (grade 3 vs grade 0): adjusted hazard ratio, 5.05; 95% confidence interval, 1.59-19.6; P = 0.005), and RFS (adjusted hazard ratio, 3.62; 95% confidence interval, 1.50-9.33; P = 0.004). Perioperative inflammation was associated with a long-term negative prognostic impact after lobectomy for lung cancer. Further prospective analysis is required to identify whether control of perioperative inflammation may improve prognosis after lung cancer surgery.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Inflammation; Non-small cell lung cancer; Prognosis; Surgery

Mesh:

Substances:

Year:  2020        PMID: 32437868     DOI: 10.1053/j.semtcvs.2020.03.019

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

1.  Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.

Authors:  Masashi Iwasaki; Shunta Ishihara; Satoru Okada; Reona Shimegi; Masanori Shimomura; Masayoshi Inoue
Journal:  Ann Surg Oncol       Date:  2022-06-02       Impact factor: 4.339

2.  Clinical significance of postoperative pulmonary complications in elderly patients with lung cancer.

Authors:  Satoru Okada; Masanori Shimomura; Shunta Ishihara; Satoshi Ikebe; Tatsuo Furuya; Masayoshi Inoue
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

3.  A multiethnic bidirectional Mendelian randomization study negates causal effects of C-reactive protein concentrations on lung cancer.

Authors:  Xiang-Rong Wu; Hao-Xin Peng; Shan Xiong; Yao-Kai Wen; Jia-Na Chen; Cai-Chen Li; Yu Jiang; Zi-Xuan Su; Jun Liu; Jian-Xing He; Wen-Hua Liang; Xiu-Yu Cai
Journal:  Transl Lung Cancer Res       Date:  2021-12

Review 4.  Perioperative Inflammatory Response and Cancer Recurrence in Lung Cancer Surgery: A Narrative Review.

Authors:  Hoon Choi; Wonjung Hwang
Journal:  Front Surg       Date:  2022-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.